Multifunctional Cyclodextrins Carriers for Pulmonary Drug Delivery: Prospects and Potential

Mehta, Piyush; Dhapte‐Pawar, Vividha

doi:10.1007/978-981-99-1923-9_8

Cited by 1 publication

(2 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug's particle size must fall within a certain range to deliver micronized drug particles in an aerosolized form to these devices. It is confirmed that sufficient medication concentration is delivered to the targeted locations within the respiratory system to achieve the intended therapeutic effect if the drug droplet/particle size is appropriate for lung deposition [8][9][10]. When compared to pMDI, dry powder formulations have better physiological and chemical stability, are propellant-free, are simple to operate and use, require minimal patient coordination, and hence offer added value when compared to pMDI [11].…”

Section: ■ Introductionmentioning

confidence: 99%

“…MTX has a structure similar to FH2, so it is competitively bound with DHFR, so the FH4 was not produced, and this affects DNA and RNA synthesis [15][16]. MTX is used to treat a variety of illnesses, including cancer, autoimmune disease, ectopic pregnancy, and asthma [10,[17][18]. Low doses suppress neutrophil chemotaxis, which has antiinflammatory benefits [19].…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methotrexate-Polymer Nanocomposites for Targeted Pulmonary Drug Delivery

AL-Sarayrah,

Hussein-Al-Ali,

Haddad

et al. 2024

Indones. J. Chem.

View full text Add to dashboard Cite

Nanocomposite formulation is a suitable technology that enables the development of successful dry powder inhalers. The methotrexate (MTX) and polyamide-disulfide (polymer) were used as a model to form MTX-polymer nanocomposites. Different amounts of the independent variable, MTX (0.025 and 0.050 g), polymer (0.05 and 0.01 g), pH (6.7 and 11.3), and across-linker ferric chloride (FeCl3) (0.05 and 0.10 g) were used. The loading efficiency and particle size were dependent variables. The optimized formula can be obtained with the highest loading efficiency and optimum particle size. This formula can be collected by using 0.025 g of drug, 0.079 g of polymer, 0.050 g of FeCl3, and pH = 6.7. The release of MTX from the nanocomposites occurs in two release steps; the first release step starts from the beginning up to 60 min, followed by a continuous release phase within 60 min. The results of the NGI analysis demonstrated that 28.1% of the nominated dose in each puff reached the lower parts of the respiratory system, an indication that the nanocomposites can be used in the delivery of MTX as a respiratory system.

show abstract

Section: ■ Introductionmentioning

confidence: 99%